SIRION Biotech Participates in Gene Therapy Expert Panel Discussion at the Piper Jaffray GenomeRx Symposium
(PresseBox) - SIRION Biotech GmbH enables its customers to advance the field of gene therapy through multiple proprietary viral vector platforms. The company today announced that its Chief Technology Officer, Christian Thirion, Ph.D., yesterday participated on a panel with leading gene therapy industry experts covering the regulatory needs in clinical development at the Piper Jaffray GenomeRx Symposium at the Yale Club in New York City.
"It's an honor to be part of such distinguished panel as the field of gene therapy continues to deliver important advances to patients. At SIRION, we see our role evolving as critical viral vector supplier across multiple proprietary platforms, said Chrisitian Thirion, Ph.D., Chief Technology Officer."
Started in 2006 in Munich, SIRION Biotech today has partnered with more than 100 clients in 300 projects across the globe. The company has raised more than $8M in venture financing from European funds since it's inception. SIRION Biotech's customers include leading academic and pharmaceutical and biotechnology companies.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Started in 2006 in Munich, SIRION Biotech today has partnered with more than 100 clients in 300 projects across the globe. The company has raised more than $8M in venture financing from European funds since it's inception. SIRION Biotech's customers include leading academic and pharmaceutical and biotechnology companies.
Datum: 24.06.2014 - 09:00 Uhr
Sprache: Deutsch
News-ID 1299724
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried
Phone:
Kategorie:
Handcrafts
Anmerkungen:
Diese Pressemitteilung wurde bisher 677 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SIRION Biotech Participates in Gene Therapy Expert Panel Discussion at the Piper Jaffray GenomeRx Symposium
"
steht unter der journalistisch-redaktionellen Verantwortung von
SIRION BIOTECH GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
